Both FXR and PPARα/δ agonists have been studied in late-stage clinical trials to treat NASH, and while attractive therapeutic effects were observed for OCA and elafibranor, the individual efficacy of these compounds appears insufficient to reverse NASH. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.